Tianjin Pharmaceutical Da Ren Tang issues September update on subsidiary bankruptcy proceedings

SGX Filings

Sep 30

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that there have been no significant developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update on Aug, 29 2025.

The company stated on Sept, 30 2025 that it continues to monitor the proceedings, maintain communication with the court and the appointed administrator, and will provide further monthly updates in line with Rule 704(23) of the Singapore Exchange Listing Manual.

Shareholders and potential investors were advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115010552"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115010552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115010552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 18:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115010552","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang issues September update on subsidiary bankruptcy proceedings","media":"SGX Filings","content":"<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that there have been no significant developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update on Aug, 29 2025.</p>\n<p>The company stated on Sept, 30 2025 that it continues to monitor the proceedings, maintain communication with the court and the appointed administrator, and will provide further monthly updates in line with Rule 704(23) of the Singapore Exchange Listing Manual.</p>\n<p>Shareholders and potential investors were advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang issues September update on subsidiary bankruptcy proceedings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang issues September update on subsidiary bankruptcy proceedings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2025-09-30 18:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that there have been no significant developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update on Aug, 29 2025.</p>\n<p>The company stated on Sept, 30 2025 that it continues to monitor the proceedings, maintain communication with the court and the appointed administrator, and will provide further monthly updates in line with Rule 704(23) of the Singapore Exchange Listing Manual.</p>\n<p>Shareholders and potential investors were advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"达仁堂","start_time":0,"source_url":"","article_id":"1115010552","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115010552","pubTimestamp":1759227251,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that there have been no significant developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂"},"translate_title":"天津医药大仁堂发布9月子公司破产程序更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":1},"content_text":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that there have been no significant developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update on Aug, 29 2025.\nThe company stated on Sept, 30 2025 that it continues to monitor the proceedings, maintain communication with the court and the appointed administrator, and will provide further monthly updates in line with Rule 704(23) of the Singapore Exchange Listing Manual.\nShareholders and potential investors were advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}